Andropause
A gradual decline in testosterone in middle-aged and older men, far milder than menopause — a real physiological phenomenon, but one that requires intervention less often than the popular understanding of the term suggests.
Number of studies
1
Safety
Moderate
Time to effects
Not applicable — a gradual process spread over decades, not a single-point intervention.
Who it's for
Table of contents
TL;DR
A gradual decline in testosterone in middle-aged and older men, far milder than menopause — a real physiological phenomenon, but one that requires intervention less often than the popular understanding of the term suggests.
- →Understanding the mechanism helps distinguish natural aging from a real, attention-worthy hormonal deficiency
- →Points to modifiable factors (sleep, body weight, stress) that can be addressed before considering hormone therapy
- →Established diagnostic criteria (EMAS) prevent overdiagnosis and unnecessary medicalization
| Intervention type | Age-related physiological process, not a single intervention |
|---|---|
| Research level | Moderate — the mechanism is well understood, diagnostic criteria established in large cohort studies |
| Target group | Middle-aged and older men with symptoms of testosterone deficiency |
| Time to effects | Not applicable — a gradual process spread over decades |
| Preparation required | Morning testosterone, LH, and FSH testing if symptomatic deficiency is suspected |
| Status | Natural physiological process, partly modifiable through lifestyle |
Understand
Overview
Andropause is a colloquial term describing the gradual decline in testosterone levels in men with age, typically by about 1–2% per year after age 30–40. Unlike menopause in women, where the drop in estrogen is abrupt and occurs within a defined, relatively short window, the decline in testosterone in men is much gentler, spread out over decades, and does not affect all men to the same degree.
A large European cohort study (the European Male Ageing Study) established precise criteria for diagnosing so-called late-onset hypogonadism — the combination of low testosterone with specific sexual symptoms (reduced libido, erectile dysfunction, fewer morning erections) — showing that a decline in testosterone alone, without these symptoms, should not automatically be treated as a condition requiring treatment.
Who can realistically benefit from this? Middle-aged and older men experiencing real symptoms (not just a natural, asymptomatic decline in testosterone) — for them, understanding andropause as a gradual process, partly modifiable through lifestyle, helps avoid both dismissing genuine symptoms and unnecessarily medicalizing natural aging.
Mechanism of action
The decline in testosterone with age results from several overlapping processes: a gradual reduction in the number and sensitivity of testosterone-producing Leydig cells in the testes, an increase in sex hormone-binding globulin (SHBG), which limits the amount of biologically active free testosterone, and a mild weakening of signaling along the hypothalamic-pituitary axis with age.
These processes also overlap with modifiable lifestyle factors — an increase in body fat (which aromatizes testosterone into estrogen), worsening sleep quality, and mounting chronic stress, all of which lower testosterone independently of biological age. This is why part of the decline attributed to andropause is, in practice, sometimes the result of accumulated lifestyle factors rather than aging alone.
Reduction in Leydig cell number
With age, the number and sensitivity of the testicular cells responsible for testosterone production decreases.
Rise in SHBG
Rising sex hormone-binding globulin levels with age limit the amount of biologically active free testosterone.
Mild weakening of the hypothalamic-pituitary axis
The hormonal signaling that drives testosterone production weakens slightly with age.
Overlapping lifestyle factors
Increased body fat, poorer sleep, and chronic stress further lower testosterone independently of age itself.
Evidence: moderate — based on 1 study in this database.
Benefits
Common myths
MythAndropause is the male equivalent of menopause, with a similarly abrupt course.
FactThe decline in testosterone in men is far gentler and more drawn out over time than the decline in estrogen in women during menopause — this is a qualitatively different process.
MythEvery aging man with lower testosterone has andropause requiring treatment.
FactDiagnosis requires the co-occurrence of low testosterone and specific sexual symptoms — an age-related decline alone, without symptoms, does not meet clinical criteria.
Practice
Frequently asked questions
The gradual decline in testosterone usually begins after age 30–40, but the pace and severity of symptoms vary widely between individuals.
No — only the co-occurrence of low testosterone and real symptoms justifies considering therapy, and part of the decline can sometimes be reversed through lifestyle changes.
Andropause symptoms are nonspecific, so diagnosis requires testing testosterone levels and ruling out other causes (hypothyroidism, depression, sleep apnea) before attributing symptoms to age alone.
Dosage & timing
Typical dose
Not applicable — a physiological process, not a dosed intervention
Form
Diagnostics: morning total testosterone, free testosterone, SHBG, LH, FSH if symptomatic deficiency is suspected
Diagnosis requires the co-occurrence of low testosterone and specific symptoms — not age alone or a single borderline result.
Best times to take it
- Testosterone testing should always be done in the morning, due to the diurnal rhythm of secretion
Safety
Side effects & contraindications
Possible side effects
Not applicable — this entry describes a physiological process, not an intervention
Contraindications
Not applicable
Interactions
Not directly applicable — see the TRT entry regarding potential interactions of hormone therapy, if pursued
Is it worth taking?
Who it's for
- Middle-aged and older men with symptoms suggesting testosterone deficiency
- Men wanting to understand the natural course of hormonal changes with age
Not for
- Not applicable
Evidence
Worth knowing
The European Male Ageing Study (EMAS) is one of the largest cohort studies to establish criteria for diagnosing late-onset hypogonadism.
Testosterone in men typically declines by about 1–2% per year after age 30–40 — a much slower pace than the popular notion of 'male menopause' suggests.
Studies
Late-onset hypogonadism should only be diagnosed when low testosterone co-occurs with specific sexual symptoms — an age-related decline in the hormone level alone, without these symptoms, does not meet the diagnostic criteria.
Wu FC et al. (European Male Ageing Study), New England Journal of Medicine, 2010
Identification of Late-Onset Hypogonadism in Middle-Aged and Elderly Men
Strong evidenceWu FC, Tajar A, Beynon JM, et al. · New England Journal of Medicine · 2010
A large European cohort study (EMAS) establishing criteria for diagnosing late-onset hypogonadism based on the co-occurrence of low testosterone and specific sexual symptoms.
View studySources & bibliography
Citations are illustrative for this demo version and require full bibliographic verification by the editorial team before production publication.
Compare with similar entries
About the authors of this entry
Author
dr Piotr ZielińskiEndocrinologist
Piotr reviews content on hormones, metabolic health and supplement pharmacology.
131 publications on this site
Medical review
dr Anna KowalczykEditor-in-Chief, Molecular Biology
Anna oversees the editorial process and scientific review of every publication in the knowledge base. She previously researched autophagy and mitochondrial biology.
50 publications on this site
Related entries
4.7Testosterone
The primary anabolic hormone — its natural level depends heavily on sleep, resistance training, body composition and fat mass.
4.4TRT — Administration Forms: Injections, Gels, and Patches
Injections, transdermal gels, and patches — the three main forms of testosterone replacement therapy differ in blood-concentration profile, ease of use, and the risk of transferring the hormone to other people.
4.6Hypogonadism — Diagnosis and Criteria for TRT Eligibility
Not every low testosterone result means hypogonadism requiring treatment. We explain which laboratory and symptomatic criteria must be met before TRT becomes a justified option.
4.7TRT — Side Effects and Therapy Monitoring
Erythrocytosis, fertility impact, PSA screening, and the cardiovascular risk question — what testosterone replacement therapy safety actually involves and how it's monitored.
4.7TRT (Testosterone Replacement Therapy) — What Is It and Who Is It For?
TRT isn't a supplement for fatigue — it's pharmacological treatment for a confirmed testosterone deficiency, with a real but limited list of benefits and an equally real list of people who simply don't qualify for it.
4.7What Tests Are Needed Before TRT? The Complete Pre-Treatment Testing List
Before a physician can qualify a patient for testosterone therapy, a far broader panel of tests is needed than testosterone level alone. The full list of blood tests, symptom questionnaires, and criteria that determine whether TRT is safe and appropriate.
4.7How Often to Test Testosterone on TRT? Monitoring Schedule and Checkups
Starting testosterone therapy isn't the end of diagnostics — it's the start of a new, recurring rhythm of checkups. We explain which tests happen at month 3, which at year one, and which need repeating for as long as therapy continues — and how the schedule differs between injectable and gel forms.
4.7TRT and Your Heart — Does Testosterone Therapy Raise Heart Attack Risk?
For a decade, testosterone therapy operated under the shadow of an FDA warning about heart attack risk. The large randomized TRAVERSE trial from 2023 finally gave a clear answer — though not as simple as the headlines suggested. We walk through the whole story, from controversial observational studies to where the evidence stands today.
Related articles
PoradnikiTRT or Lifestyle Change? What Actually Raises Testosterone Before You Consider Therapy
Before considering testosterone replacement therapy, it's worth checking how much sleep, training, and fat loss can realistically achieve — and when these interventions genuinely aren't enough.
July 29, 2026
PoradnikiLow Testosterone After 40 — Normal Aging or a Problem Worth Treating?
Testosterone in a forty-something man genuinely can be lower than it was at 25 — but "that's normal for your age" isn't an answer in itself. We explain how to tell a mild, expected decline apart from a situation that deserves proper testing and a real decision.
August 15, 2026
PoradnikiLow Testosterone After 50 — Symptoms, Testing, and Treatment Options
Past fifty, the risk-benefit math on low testosterone looks different than it does at 40 — more coexisting conditions to factor in, more weight given to prostate and cardiac screening, but one topic usually stops being a problem: fertility.
August 15, 2026
PoradnikiLow Testosterone: 12 Symptoms Men Often Don't Connect to Their Hormones
Fatigue, a flatter mood, trouble building fitness despite training — most men blame these on age, stress, or a lack of willpower. We look at which symptoms are actually worth linking to low testosterone, and why none of them, on its own, proves anything.
August 15, 2026
Comments (2)
- KW
Kasia W. 2 weeks ago
Very clearly explained, especially the interactions section — I hadn't seen it laid out this well anywhere else.
- MT
Marek T. a month ago
Are you planning to update this with the newest study from this year? I saw an interesting meta-analysis.
